Home › Glioma › North Carolina
Glioma clinical trials in North Carolina
16 studies for Glioma are looking for participants at sites in North Carolina.
Cities in North Carolina
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- Atrium Health Levine Cancer Institute, Charlotte
- Atrium Health Wake Forest Baptist, Winston-Salem
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07326566ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Duke University Medical Center, Durham
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated Oct 23, 2026 · NCT06838676SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT05303519A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Levine Children's Hospital- Pediatric Neuro-Oncology, Charlotte
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610Targeted Pediatric High-Grade Glioma Therapy
- Duke University Health System, Durham
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Duke University Health System, Durham
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
- Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT05609994PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Duke Cancer Center, Durham
RecruitingPhase 2
Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481MRI in High-Grade Glioma Patients Undergoing Chemoradiation
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Recruiting
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05212272A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Atrium Health Wake Forest Baptist - Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Lerapolturev (PVSRIPO) in GBM
- Duke University Medical Center, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 20, 2026 · NCT06177964Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Duke University Health System, Durham
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
- Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT04547777Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Duke University Health System, Durham
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
- Duke University, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT06126744A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Duke University Health System, Durham
RecruitingEarly phase 1
Up to age 21 · All sexes · Updated Mar 18, 2026 · NCT04655404From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.